About: Ace revisited: A new target for structure-based drug design

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Ace revisited: A new target for structure-based drug design Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Ace revisited: A new target for structure-based drug design
Creator	Ehlers, Mario Sturrock, Edward Acharya, K Riordan, James
Source	PMC
abstract	Current-generation angiotensin-converting enzyme (ACE) inhibitors are widely used for cardiovascular diseases, including high blood pressure, heart failure, heart attack and kidney failure, and have combined annual sales in excess of US $6 billion. However, the use of these ACE inhibitors, which were developed in the late 1970s and early 1980s, is hampered by common side effects. Moreover, we now know that ACE actually consists of two parts (called the N- and C-domains) that have different functions. Therefore, the design of specific domain-selective ACE inhibitors is expected to produce next-generation drugs that might be safer and more effective. Here we discuss the structural features of current inhibitors and outline how next-generation ACE inhibitors could be designed by using the three-dimensional molecular structure of human testis ACE. The ACE structure provides a unique opportunity for rational drug design, based on a combination of in silico modelling using existing inhibitors as scaffolds and iterative lead optimization to drive the synthetic chemistry.
has issue date	2003-01-01(xsd:dateTime)
bibo:doi	10.1038/nrd1227
bibo:pmid	14668810
has license	no-cc
sha1sum (hex)	a570ae9a59df3c57e076252949e6036bdfb5e0e6
schema:url	https://doi.org/10.1038/nrd1227
resource representing a document's title	Ace revisited: A new target for structure-based drug design
has PubMed Central identifier	PMC7097707
has PubMed identifier	14668810
schema:publication	Nat Rev Drug Discov
resource representing a document's body	covid:a570ae9a59df3c57e076252949e6036bdfb5e0e6#body_text
is schema:about of	named entity 'structure-based drug discovery' named entity 'high-throughput' named entity 'proteome' named entity 'bioinformatics' named entity 'druggable' named entity 'nitric oxide' named entity 'binding sites' named entity 'ACE inhibitors' named entity 'chloride ions' named entity 'Drosophila melanogaster' named entity 'Ang II' named entity 'peptides' named entity 'zinc' named entity 'quinaprilat' named entity 'lisinopril' named entity 'ACE inhibitors' named entity 'Lys' named entity 'peptide bond' named entity 'cardiovascular complications' named entity 'LH-RH' named entity 'chloride' named entity 'angiotensin-converting enzyme' named entity 'active-site' named entity 'ACE inhibitors' named entity 'Ang II' named entity 'carboxypeptidase' named entity 'metallopeptidases' named entity 'cardiovascular morbidity' named entity 'physiological function' named entity 'zinc' named entity 'glucosidase' named entity 'peptides' named entity 'enzyme' named entity 'directly proportional' named entity 'blood pressure' named entity 'paracrine growth factor' named entity 'glutamate' named entity 'drug design' named entity 'complement' named entity 'lysyl' named entity 'nitrogen' named entity 'fibrinolytic' named entity 'orally active' named entity 'dipeptidase' named entity 'carboxypeptidase' named entity 'enalaprilat' named entity 'vasodilatory' named entity 'plasma' named entity 'asparagine' named entity 'clinical trials' named entity 'ACE inhibitors' named entity 'radioligand' named entity 'desensitization' named entity 'methyl groups' named entity 'lysine' named entity 'N-terminal domain' named entity 'ACE' named entity 'metalloproteases' named entity 'morbidity' named entity 'captopril' named entity 'luteinizing hormone-releasing hormone' named entity 'active-site' named entity 'conserved residues' named entity 'enalaprilat' named entity 'SEQUON' named entity 'metalloenzyme' named entity 'Ang II' named entity 'peptide' named entity 'ACE inhibitors' named entity 'peptides' named entity 'titrations' named entity 'lisinopril' named entity 'ACE2' named entity 'ACE inhibitors' named entity 'P 2' named entity 'S 1' named entity 'enzyme responsible' named entity 'ACE2'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software